
The Maryland Racing Commission has re-issued advisories on use of thyroid supplements and substances containing CBD, and also a reminder regarding horses on the vet’s list.
Thyroid supplementation is prohibited, and trainers may not have thyroid supplements in their premises on the racetrack or training centers, nor may they administer such supplements, unless the following conditions are met:
Cannabidiol (CBD), a constituent of cannabis, is not permitted for use in horses. It is available in many over-the-counter nutritional supplements and in one FDA-approved prescription drug use to control childhood epilepsy.
The Racing Medication and Testing Consortium in an advisory noted there is risk of contamination in CBD products given the lack of regulatory oversight for extraction of CBD from the cannabis plant. There is no withdrawal guidance for the substance, which can and has produced positive test findings from racehorse samples.
CBD is categorized by the Association of Racing Commissioners International as a Class 2 substance in the Penalty B category. However, should a CBD product contain more than 0.3% tetrahydrocannabinol—commonly known as THC—it is a Class 1 substance in the Penalty A category on the ARCI list.
Regarding the vet’s list, horsemen are reminded that when they obtain a racehorse from another party, it is their responsibility to check with the Racing Office and/or regulatory veterinarians to ensure the horse is not on the vet’s list or any other list that would make the horse ineligible to run.




The MTHA will hold a public meeting Thursday, October 22, 2026, at 11 a.m. Eastern Time via Zoom to discuss a proposed digital auction process for horses receiving two or more claims in a claiming race.

An October 7 Daily Record article about proposed Maryland Racing Commission regulations has generated questions about increased penalties, medication enforcement and the state’s investment in Thoroughbred racing.
